-
Bifendate Attenuates Hepatic Steatosis in Mice
2026-08-30
The reference study showed that Bifendate, or DDB, consistently reduced hepatic cholesterol and triglyceride accumulation across several diet- and cholesterol-induced mouse models. Its selective effect on liver lipids, without parallel serum lipid lowering, distinguishes it from fenofibrate and frames DDB as a liver-focused regulator of lipid handling rather than a conventional systemic hypolipidemic agent.
-
Targeted EPO mRNA Nanoparticles for Spinal Cord Repair
2026-08-29
The reference study develops a mannose-modified lipid nanoparticle that delivers erythropoietin mRNA to CD206-enriched inflammatory macrophages and microglia after spinal cord injury. In mice, localized EPO production was associated with reduced neuroinflammation and ferroptosis, preservation of neural structures, and improved motor recovery, although dose, biodistribution, and translational questions remain.
-
Gap19: From Cx43 Selectivity to Translation
2026-08-28
A thought-leadership guide to using Gap19 as a mechanistically resolved Cx43 hemichannel probe across astrocyte, ischemia, and inflammation models, with practical guidance for experimental design and translational interpretation.
-
EZ Cap™ Cre mRNA (m1Ψ): Assay Strategy
2026-08-28
EZ Cap™ Cre mRNA (m1Ψ) is a transient Cre recombinase mRNA for precise Cre-lox studies. This guide shows how to use it not only as a gene editing mRNA, but also as a practical probe for separating transcript quality, delivery performance, and recombination biology.
-
EZ Cap™ OVA mRNA for Immune Model Design
2026-08-27
EZ Cap™ OVA mRNA provides a standardized Ovalbumin mRNA platform for reproducible immune response, gene expression, and delivery studies. This article explains how Cap 1 chemistry, poly(A) design, and emerging low-inflammatory lipid delivery research can inform assay decisions without overstating translational evidence.
-
Relapsed Childhood ALL and Thioguanine Sensitivity
2026-08-27
The reference study examined whether immunophenotypic lineage predicts ex vivo drug resistance in childhood relapsed acute lymphoblastic leukaemia. Its central finding was that relapsed T-cell ALL was more sensitive to the thiopurines mercaptopurine and 6-thioguanine than B-cell precursor ALL, supporting lineage-informed evaluation of thiopurine use while not explaining the poorer clinical prognosis of T-cell disease.
-
EZ Cap™ OVA mRNA for Better Immune Models
2026-08-26
EZ Cap™ OVA mRNA provides a defined Ovalbumin mRNA cargo for immune assays, gene expression studies, and vaccine development research. This article explains how Cap 1 design, delivery-system inflammation, and assay controls should be evaluated together for more interpretable results.
-
Propidium iodide Workflows for Cell Analysis
2026-08-26
Propidium iodide provides a practical readout of membrane failure, DNA content, and late-stage cell death across microscopy and flow cytometry. This guide connects validated PI workflows with lactoferrin-processing research, showing how to separate membrane integrity from metabolic or apoptotic endpoints while avoiding common staining artifacts.
-
Firefly Luciferase mRNA: Mechanism & Workflow
2026-08-25
Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) is a modified, capped reporter transcript for gene expression, cell viability, and in vivo imaging assays. Its defined nucleotide chemistry, poly(A) tail, storage format, and luciferase readout support reproducible transfection controls, but signal remains dependent on delivery, substrate access, cellular ATP, and optical conditions.
-
Epalrestat Workflows for Polyol Pathway Research
2026-08-25
Epalrestat gives researchers a practical way to perturb aldose reductase and connect polyol pathway activity with oxidative stress, diabetic neuropathy, and cancer-metabolism phenotypes. This workflow-focused guide covers solvent handling, assay design, pathway controls, and the limits of extending aldose reductase findings into a Parkinson’s disease model or cancer study.
-
ABT-199 (Venetoclax) Apoptosis Workflows
2026-08-24
Use ABT-199 (Venetoclax) as a selective BCL-2 probe for apoptosis assays in B-cell, NHL, and AML models. This practical guide covers stock handling, mitochondrial readouts, combination testing, and how to interpret findings from a colorectal cancer organoid study without overstating what the evidence proves.
-
Adipose-Neural Signaling in Cardiac Arrhythmia
2026-08-24
Fan et al. developed a stem cell-based coculture model showing how epicardial adipose tissue can influence cardiac electrical instability through a leptin–sympathetic neuron–NPY/Y1R pathway. The study connects this signaling cascade to NCX and CaMKII activity and supports the adipose-neural axis as a mechanistic framework for arrhythmia research.
-
GRK Control of M1 Receptor Signaling Bias
2026-08-23
A 2025 study used time-resolved BRET to define how GRK2/3 and GRK5/6 differentially regulate M1 receptor coupling to G protein and β-arrestin 2. Its analysis places BQCA within a broader framework of receptor-transducer selectivity, while also showing why molecular signaling bias should not be equated directly with cognitive or therapeutic outcomes.
-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-08-22
CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for studying CDK9-dependent transcription elongation, P-TEFb activity, and defined HIV-1 research systems. It should not be used as a pan-CDK reagent, a general cell-cycle regulator, or a working solution intended for prolonged storage.
-
DiscoveryProbe FDA-approved Drug Library for Folding
2026-08-22
Convert clinically characterized compounds into a practical workflow for protein-folding rescue, phenotypic screening, and target validation. The library combines broad pharmacological coverage with ready-to-use DMSO stocks, helping teams move from a reporter hit to an orthogonal mechanism study without building a compound collection from scratch.